• N1-Methylpseudo-UTP for Accurate RNA Workflows

  2026-09-27

  Learn how to incorporate N1-Methyl-Pseudouridine-5'-Triphosphate into in vitro transcription and assess RNA output without confusing translation yield with fidelity. A landmark study supports accurate translation of N1-methylpseudouridine-containing mRNA, while practical controls help pinpoint synthesis, purification, and assay problems.

• CLEC5A and ISG20 in Atherosclerosis: Causal Evidence

  2026-09-26

  Zhang et al. integrate GEO expression data, eQTL evidence, and Mendelian randomization to prioritize CLEC5A and ISG20 as genes positively associated with atherosclerosis risk, with HOXA2 showing an opposing association. Experimental findings strengthen the case for elevated ISG20 in atherosclerotic models, while the study’s observational and genetic design leaves its precise cellular mechanisms and therapeutic relevance to be established.

• CFDA SE Cell Tracer Kit: Practical Workflow

  2026-09-25

  The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell lineage tracing and cell proliferation studies when a durable label is needed across several days. It is not a reversible or short-term labeling method, and labeling conditions should be validated for each cell type and assay.

• Radioiodinated Balsalazide for Ulcerative Colitis Imaging

  2026-09-25

  This mouse study developed radioiodinated balsalazide and evaluated its stability and distribution in normal and ulcerated-colon models. The reported high uptake in ulcerated colon supports further investigation as an imaging approach, while the animal-only evidence and limited information on tissue specificity constrain clinical interpretation.

• E-4031: From hERG Blockade to Translational Insight

  2026-09-24

  E-4031 is a precise experimental perturbation for studying hERG-mediated repolarization and arrhythmia risk. This article connects its channel-level action to tissue models, offers practical workflow guidance, and explains what translational researchers can—and cannot—infer from the resulting phenotypes.

• Mifepristone (RU486): Receptor Heterogeneity in Cancer

  2026-09-24

  Mifepristone (RU486) is usually discussed as a progesterone receptor antagonist, but its research value also depends on how receptor heterogeneity is measured. This article connects that experimental-design question to prostate cancer evidence on androgen receptor heterogeneity—without treating the two receptors or drugs as interchangeable.

• CK2 and ERK8 Inhibitor: B7464 Research Guide

  2026-09-23

  B7464 is a small molecule inhibitor listed for CK2 and ERK8 research, chemically identified as 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid. Its product specifications support research planning, but do not establish a dose, selectivity profile, or effect on viral condensates.

• Cy5 TSA Fluorescence System Kit: Practical Workflow

  2026-09-23

  Translate weak immunostaining, cellular markers, and RNA signals into crisp Cy5 fluorescence with a workflow designed for IHC, ICC, and FISH. The approach is especially useful for mapping the NET-DNA–CCDC25–IL-22 axis in intestinal epithelial repair while conserving scarce antibodies and probes.

• ML385 for Reliable NRF2 Assays

  2026-09-22

  This scenario-based guide explains how ML385, SKU B8300, can strengthen cell viability, oxidative-stress, ferroptosis, and non-small cell lung cancer research workflows. It connects product specifications with published NRF2 evidence while emphasizing controls, dose interpretation, handling, and vendor reliability.

• GPNMB Model Predicts ESCC Immunotherapy Response

  2026-09-22

  This study identifies circulating soluble GPNMB as a functional marker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma proteomics, CAF–epithelial niche features, mechanistic immune assays, and clinical variables, the authors develop a multimodal framework for response prediction and patient stratification.

• Amikacin disulfate: Assay Workflows & Troubleshooting

  2026-09-21

  Build more informative antibiotic mechanism studies with a water-soluble aminoglycoside that supports bacterial, ribosomal, and protein–drug interaction assays. This guide translates lysozyme-binding findings into practical workflow choices while separating mechanistic evidence from starting-point protocol recommendations.

• Pseudo-UTP Workflows for mRNA Synthesis

  2026-09-21

  Learn how Pseudo-UTP can be integrated into in vitro transcription, mRNA screening, and RNA quality-control workflows without treating pseudouridine as a universal substitute for every modified nucleotide. This practical guide connects reaction design, assay interpretation, troubleshooting, and translational RNA applications.

• TCAIM Control of OGDH in Mitochondrial Metabolism

  2026-09-20

  Wang et al. identify TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The work expands the role of mitochondrial proteostasis beyond protein folding, showing that co-chaperone-dependent control of OGDH abundance can suppress OGDH complex activity and reshape carbohydrate metabolism.

• JSH-23 and the NF-κB Inflammation Checkpoint

  2026-09-19

  JSH-23 is an NF-κB inhibitor that separates p65-dependent transcription from upstream IκB degradation. This article applies that mechanistic distinction to inflammation research and interprets its value alongside TLR–NF-κB–AIM2 signaling in viral infection studies.

• Refining In Vitro Drug Response Metrics in Cancer

  2026-09-18

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measurements capture different relationships between proliferative arrest and cancer-cell death. The framework encourages time-aware, paired response measurements that can make preclinical drug comparisons more interpretable and biologically informative.

550 records 3/37 page Previous Next 12345 下5页 Last page